<DOC>
	<DOCNO>NCT02640950</DOCNO>
	<brief_summary>Transcranial Magnetic Stimulation ( TMS ) increasingly accept neurostimulation- base treatment major depressive disorder . While grow anecdotal database support use bipolar depression investigator propose collect open label efficacy safety data small population patient clinically verify bipolar disorder .</brief_summary>
	<brief_title>An Open Label Trial TMS Therapy Bipolar Depression</brief_title>
	<detailed_description>The investigator propose screen patient bipolar depression I II , already acceptable mood stabilization . They may may antidepressants time screen subject antidepressant would take complete screen phase . Those patient depression least moderate severity without significant symptom activation mania start course open label TMS treatment 35 session . Safety efficacy assessment do weekly . Patients complete course treatment meet remission criterion ( MADRS score &lt; 10 ) end 30 treatment , whichever come first . Patient still judge improve treatment 25 treatment 30 eligible complete five addition treatment discretion site 's principal investigator . Patients meet response criterion ( MADRS score decrease least 50 % ) complete full course 30 35 TMS session . Patients withdraw safety concern , particularly onset activation suggestive mania mixed state . Patients meet response remission criterion follow monthly six month evaluate durability response . They standard mood stabilize medication psychotherapy per clinician 's discretion .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<criteria>Inclusion Criteria Phase II : 1 . Must least 18 year old . 2 . Must meet DSM5 criterion bipolar ( either I II ) depression clinical interview M.I.N.I . The duration current depressive episode must least 4 week longer 3 year length . 3 . Should MADRS score least 20 screening , YMRS score less 12 CGI score least 4 . 4 . Must sign informed consent document level understanding sufficient provide inform consent communicate investigator site personnel . 5 . Must mood stabilizer acceptable study physician consistent diagnosis . The mood stabilizer must stable dose least four day start TMS treatment . 6 . If female childbearing potential , patient must 1. negative urine pregnancy test screening , 2. nursing planning pregnancy , 3. medically acceptable method birth control acceptable principal investigator . Choices contraception meet study requirement Intrauterine device Hormonal contraception ( estrogencontaining birth control pill , Vaginal ring , patch , injection implant ) Latex condom spermicide Diaphragm spermicide Cervical cap spermicide Females childbearing potential abstinent enroll study . Exclusion Criteria Phase II : 1 . May directly affiliate Sheppard Pratt Clinical Research Programs immediate family Research Programs personnel . 2 . Must another primary Axis I diagnosis . 3 . The subject must stop antidepressant less two week start TMS treatment unable discontinue antidepressant therapy . 4 . Should previous history psychosis substance dependence abuse within six month prior Screening 5 . Presence Axis II disorder felt investigator potentially interfere study compliance would exclude potential participant . 6 . Should prior intolerance TMS significant lack response adequate trial TMS . 7 . Should lifetime history lack response ECT VNS . 8 . Should medical condition likely interfere safe study participation . 9 . Women childbearing potential use medically accept mean contraception engage sexual intercourse exclude , well woman pregnant breastfeeding . 10 . Positive urine screen substance abuse exclude patient , exception benzodiazepine . A satisfactory explanation opinion investigator along negative repeat screen prior Visit 2 possibly acceptable . 11 . Current suicide risk , evidence : 1 . It judgment investigator patient may risk suicide 2 . The patient rat `` yes '' question 4 question 5 Screening CSSRS 3 . The patient attempt suicide within past 12 month prior Screening . 12 . History head injury , epilepsy seizure disorder , nonremovable metallic implant object around head . Inclusion Criteria Phase III Patients meet MADRS criterion response remission enter Phase III , six month followup phase study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>